Cover Image
市場調查報告書

心肌梗塞治療藥的全球市場:2016年∼2020年

Global Myocardial Infarction Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 354392
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
心肌梗塞治療藥的全球市場:2016年∼2020年 Global Myocardial Infarction Drugs Market 2016-2020
出版日期: 2016年03月08日 內容資訊: 英文 75 Pages
簡介

全球心肌梗塞治療藥的市場,預計從2016年到2020年以0.41%的年複合成長率 (CAGR) 擴大。

本報告提供全球心肌梗塞治療藥的市場調查,市場及產品概要,主要供應商的提供產品,疾病概要,開發平台趨勢,整體市場及各藥物類別、心電圖模式、藥物類型、地區的市場規模的變化與預測,市場的影響因素分析,主要趨勢,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商的產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點
  • 主要的購買標準

第5章 疾病概要

  • 心肌梗塞的各種類型
  • 病理生理學
  • 風險因素
  • 診斷
  • 管理

第6章 流行病學、經濟負擔

第7章 開發平台分析

  • Canakinumab
  • MyoCell
  • MultiStem therapy
  • CLBS10
  • Prochymal
  • Revascor
  • CicloMulsion
  • PP-099
  • NP202
  • CAP-1002
  • Revacept
  • CSL112

第8章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第9章 市場分析:各類藥物

  • β- 阻斷劑
  • ACE抑制劑(血管收縮素轉換酵素抑制劑)
  • ARB
  • 血管擴張藥
  • 抗血栓藥
  • 血栓溶解藥
  • 糖蛋白IIb/IIIa抑制劑
  • 抗異常脂質血症藥
  • 鈣拮抗劑
  • 止痛藥

第10章 市場分析:各心電圖模式

  • NSTEMI (非ST上升型心肌梗塞)
  • STEMI (ST上升型心肌梗塞)

第11章 市場分析:各類型

  • 品牌藥
  • 學名藥

第12章 市場分析:各地區

  • 全球市場的變化與預測:各地區
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第13章 市場成長因素

  • 老年人口的增加
  • 座位位許多生活方式
  • 肥胖的擴大
  • 慢性疾病高的發病率

第14章 市場成長因素的影響

第15章 市場課題

  • 診斷的延遲
  • 替代療法
  • 學名藥的廣泛的利用

第16章 成長因素與課題的影響

第17章 市場趨勢

  • 疾病的認知度上升
  • 策略性聯盟
  • R&D的活躍
  • 血管支架利用的擴大

第18章 業者情勢

  • 競爭模式
  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi
  • 其他卓越供應商

第19章 附錄

第20章 關於Technavio

圖表

目錄
Product Code: IRTNTR8952

About Myocardial Infarction Drugs

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

Technavio's analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • advanceCOR
  • Armaron Bio
  • Athersys
  • BioVascular
  • BMS
  • Caladrius
  • Capricor
  • CSL Behring
  • GNT Pharma
  • GSK
  • Ischemix
  • Mesoblast
  • NeuroVive
  • Osiris Therapeutics
  • PledPharma
  • RegeneRx
  • Teva Pharmaceuticals
  • TiGenix
  • US Stem Cell
  • Ventrix

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • Alternative therapies
  • For a full, detailed list, view our report

Market trend

  • Growing awareness of disease
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Disease overview

  • Types of myocardial infarction
  • Pathophysiology
  • Risk factors
  • Diagnosis
  • Management

PART 06: Epidemiology and economic burden

  • Burden of disease

PART 07: Pipeline analysis

  • Canakinumab
  • MyoCell
  • MultiStem therapy
  • CLBS10
  • Prochymal
  • Revascor
  • CicloMulsion
  • PP-099
  • NP202
  • CAP-1002
  • Revacept
  • CSL112

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by drug class

  • Beta blockers
  • ACE inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic agents
  • Thrombolytics
  • Glycoprotein IIb/IIIa inhibitors
  • Anti-dyslipidemic drugs
  • Calcium channel blockers
  • Analgesics

PART 10: Market segmentation by EKG appearance

  • NSTEMI
  • STEMI

PART 11: Market segmentation by type

  • Brand-name drugs
  • Generic drugs

PART 12: Geographical segmentation

  • Global myocardial infarction drugs market segmentation by geography 2015-2020
  • Myocardial infarction drugs market in Americas
  • Myocardial infarction drugs market in EMEA
  • Myocardial infarction drugs market in APAC

PART 13: Market drivers

  • Increase in older population
  • Sedentary lifestyle
  • Rise in obesity
  • High prevalence of chronic conditions

PART 14: Impact of drivers

PART 15: Market challenges

  • Delayed diagnosis
  • Alternative therapies
  • Extensive use of generics

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Growing awareness of disease
  • Strategic alliances
  • Increased R&D
  • Prevalent use of stent grafts

PART 18: Vendor landscape

  • Competitive scenario
  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for myocardial infarction drugs
  • Exhibit 03: Pathophysiology of myocardial infarction
  • Exhibit 04: Risk factors of myocardial infarction
  • Exhibit 05: Diagnostic techniques for myocardial infarction
  • Exhibit 06: Treatment options for myocardial infarction
  • Exhibit 07: Projected prevalence of CVDs in US
  • Exhibit 08: Projected economic burden for CVDs in US
  • Exhibit 09: Pipeline portfolio: Myocardial infarction
  • Exhibit 10: Global myocardial infarction drugs market 2015-2020 ($ billions)
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Global myocardial infarction drugs market segmentation by EKG appearance 2015
  • Exhibit 13: Global myocardial infarction drugs market segmentation by type 2015
  • Exhibit 14: Global myocardial infarction drugs market segmentation by geography 2015
  • Exhibit 15: Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 16: Myocardial infarction drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 17: Myocardial infarction drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 18: Myocardial infarction drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 19: Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 20: Impact of drivers
  • Exhibit 21: Impact of drivers and challenges
  • Exhibit 22: AstraZeneca: Business segmentation by revenue 2014
  • Exhibit 23: AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014
  • Exhibit 24: AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions)
  • Exhibit 25: AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions)
  • Exhibit 26: AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions)
  • Exhibit 27: AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions)
  • Exhibit 28: AstraZeneca: Key takeaways
  • Exhibit 29: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions)
  • Exhibit 30: Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions)
  • Exhibit 31: Bayer HealthCare: Key takeaways
  • Exhibit 32: Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions)
  • Exhibit 33: Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions)
  • Exhibit 34: Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions)
  • Exhibit 35: Eli Lilly: Key takeaways
  • Exhibit 36: Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions)
  • Exhibit 37: Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions)
  • Exhibit 38: Novartis: Key takeaways
  • Exhibit 39: Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions)
  • Exhibit 40: Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions)
  • Exhibit 41: Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions)
  • Exhibit 42: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
  • Exhibit 43: Pfizer: Key takeaways
  • Exhibit 44: Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions)
  • Exhibit 45: Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions)
  • Exhibit 46: Sanofi: Key takeaways
Back to Top